{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-064653","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.639336+00:00","generated_at":"2026-06-14T14:00:24.254385+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"ANI Pharma shareholders approve all proposals at 2023 annual meeting","bullets":["All eight director nominees elected; Thomas Haughey received 9.90M for, 4.11M against, highest against.","Ratification of EisnerAmper as FY2023 auditor approved: 14.96M for, 95.96K against.","Advisory say-on-pay approved: 13.21M for, 780.34K against, 19.91K abstain.","2023 amendment to 2022 Stock Incentive Plan approved: 12.83M for, 1.17M against.","Broker non-votes of 1.05M on all proposals except auditor ratification."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-064653","json":"https://secwatch.observer/filing/0001104659-23-064653.json","markdown":"https://secwatch.observer/filing/0001104659-23-064653.md","text":"https://secwatch.observer/filing/0001104659-23-064653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923064653/0001104659-23-064653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923064653/tm2316594d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:00:24.254385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f6f33194b657d9e46ed2d5cd12816d4f1a68d2f","claim":"ANI PHARMACEUTICALS INC shareholders approved Approval of the 2023 Stock Plan Amendment.","evidence_excerpt":"Proposal No. 4 — Approval of the 2023 Stock Plan Amendment The vote with respect to the approval of the 2023 Stock Plan Amendment was as follows: For Against Abstain Broker Non-Votes 12,825,247 1,170,827 11,650 1,048,318","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923064653/0001104659-23-064653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"20fe15f0ebc4116bb37973a9005393c64608fce6","claim":"ANI PHARMACEUTICALS INC shareholders approved Ratification of the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.","evidence_excerpt":"Proposal No. 2 — Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: For Against Abstain 14,959,216 95,962 864","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923064653/0001104659-23-064653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"6052779e5f88f6bd76cef925d18d67b3149e2db6","claim":"ANI PHARMACEUTICALS INC shareholders approved Advisory vote to approve the compensation of the Company's named executive officers.","evidence_excerpt":"Proposal No. 3 — Approval of the Say-on-Pay Proposal The vote with respect to the approval of the Company’s named executive officers, on an advisory basis, was as follows: For Against Abstain Broker Non-Votes 13,207,478 780,337 19,909 1,048,318","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923064653/0001104659-23-064653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"eb5c06e7b63a2935d9f2979fb7c5954e655c5d30","claim":"ANI PHARMACEUTICALS INC shareholders approved Election of eight directors to serve until the Company's 2024 Annual Meeting of Stockholders.","evidence_excerpt":"Proposal No. 1 — Election of the Directors The vote with respect to the election of each of the directors was as follows: Nominees For Against Abstain Broker Non-Votes Thomas Haughey 9,898,826 4,105,256 3,642 1,048,318 Nikhil Lalwani 13,804,562 191,821 11,341 1,048,318 David B. Nash, M.D. 8,752,887 5,252,899 1,938 1,048,318 Antonio R. Pera 13,404,484 601,762 1,478 1,048,318 Muthusamy Shanmugam 13,805,957 200,160 1,607 1,048,318 Renee P. Tannenbaum, Pharm.D. 13,429,350 576,916 1,458 1,048,318 Jeanne A. Thoma 11,492,066 2,511,523 4,135 1,048,318 Patrick D. Walsh 13,757,829 248,425 1,470 1,048,318","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923064653/0001104659-23-064653-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}